ES521370A0 - Un procedimiento para obtener un polidoma. - Google Patents

Un procedimiento para obtener un polidoma.

Info

Publication number
ES521370A0
ES521370A0 ES521370A ES521370A ES521370A0 ES 521370 A0 ES521370 A0 ES 521370A0 ES 521370 A ES521370 A ES 521370A ES 521370 A ES521370 A ES 521370A ES 521370 A0 ES521370 A0 ES 521370A0
Authority
ES
Spain
Prior art keywords
polydoma
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES521370A
Other languages
English (en)
Other versions
ES8504461A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES8504461A1 publication Critical patent/ES8504461A1/es
Publication of ES521370A0 publication Critical patent/ES521370A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES521370A 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma. Granted ES521370A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES8504461A1 ES8504461A1 (es) 1985-04-16
ES521370A0 true ES521370A0 (es) 1985-04-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Granted ES527963A0 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES527963A Granted ES527963A0 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES521370A0 (es)
FI (2) FI834529A0 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
ATE64622T1 (de) * 1984-04-23 1991-07-15 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
DE69130561T2 (de) * 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
IE921342A1 (en) * 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
EP1740530B8 (en) 2004-03-16 2017-03-01 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6473418B2 (ja) * 2013-10-10 2019-02-20 幸成 加藤 抗ポドプラニン抗体
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CA3110096A1 (en) * 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
CA3139809A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4362977A1 (en) 2021-06-29 2024-05-08 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
FI834529A7 (fi) 1983-12-09
EP0105360A1 (en) 1984-04-18
GB2128631B (en) 1987-02-25
ES8504461A1 (es) 1985-04-16
CA1213229A (en) 1986-10-28
ES8604424A1 (es) 1986-02-01
ATA901883A (de) 1991-10-15
GB8530309D0 (en) 1986-01-22
GB2168998B (en) 1987-03-04
WO1983003679A1 (en) 1983-10-27
ES538727A0 (es) 1986-02-01
GB2169921B (en) 1987-03-04
IT8320548A0 (it) 1983-04-12
GB8332646D0 (en) 1984-01-11
FI834529L (fi) 1983-12-09
AT394577B (de) 1992-05-11
GB2169921A (en) 1986-07-23
GB8530310D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02
JPS6312276A (ja) 1988-01-19
ES545247A0 (es) 1986-05-16
AU1555983A (en) 1983-11-04
JPH0753600A (ja) 1995-02-28
FI900212A0 (fi) 1990-01-15
ES8506091A1 (es) 1985-06-16
FI834529A0 (fi) 1983-12-09
FI900212A7 (fi) 1990-01-15
ES533930A0 (es) 1985-12-01
JP2562002B2 (ja) 1996-12-11
CH672796A5 (es) 1989-12-29
AU550486B2 (en) 1986-03-20
GB2167086A (en) 1986-05-21
ES8607386A1 (es) 1986-05-16
ES537257A0 (es) 1986-04-01
ES8603080A1 (es) 1985-12-01
ES533931A0 (es) 1985-06-16
ES8606655A1 (es) 1986-04-01
ES8503441A1 (es) 1985-02-16
GB2168998A (en) 1986-07-02
JPH0753119B2 (ja) 1995-06-07
GB8530308D0 (en) 1986-01-22
IT1219778B (it) 1990-05-24
ES527963A0 (es) 1985-02-16
GB2167086B (en) 1987-03-04
EP0105360A4 (en) 1986-07-08

Similar Documents

Publication Publication Date Title
ES533930A0 (es) Un procedimiento para obtener un polidoma
ES519925A0 (es) Un procedimiento para formar un material absorbente.
ES534202A0 (es) Un procedimiento para preparar nuevos compuestos de cefem.
ES537668A0 (es) Un procedimiento para preparar n-formil-3-fenoxi-1-azetidincarboxamidas
ES523195A0 (es) Un procedimiento para preparar alquil-glicosidos
ES523064A0 (es) Procedimiento para preparar azetidinas.
ES519652A0 (es) Un procedimiento para obtener s-adenosil-metionina.
AR231308A1 (es) Un procedimiento para preparar 1-be-d-ribofuranosil-1,2,4-triazolcarboxamida rivavirina
ES520364A0 (es) Un procedimiento para preparar compuestos de cefem.
FI73942B (fi) Med utloesare manoevrerbar foerdelningsventil foer en under tryck staoende behaollare.
ES523193A0 (es) Un procedimiento para preparar 3-fenoxi-1-azetidincarbo-xznmidas
ES518758A0 (es) Un procedimiento para preparar azetidinas.
ES538192A0 (es) Un procedimiento para preparar un 2-bromo-6b-9a - difluoro-11b, 17a, 21-trihidroxi-1, 4-pregnadien-3, 20-diona-17, 21-diester
ES520531A0 (es) Procedimiento para preparar tioeteres.
ES521813A0 (es) Procedimiento para preparar alcohil-polisacaridos.
ES519936A0 (es) Un procedimiento para preparar derivados de pirimidona.
ES527278A0 (es) Un procedimiento para obtener 2,5-anhidro-3,4,6-tri-o-acil-d-alonselenocarboxamida
ES524772A0 (es) Un procedimiento para preparar fenilanilinas-n.sustituidas.
ES522716A0 (es) Un procedimiento para preparar un derivado de pirazol.
ES523277A0 (es) Un procedimiento para preparar peptidos.
ES527108A0 (es) Un procedimiento para preparar 2-alcoxi-5-(piridinil) piridinas
NO157221C (no) Fremgangsmaate for elektroplettering.
ES520370A0 (es) Un procedimiento para obtener derivados de isoxazolopirimidina.
ES520879A0 (es) Un procedimiento para preparar 1-hidroxietil-1h-tetrazol-5-tiolopcionalmente protegido.
ES527247A0 (es) Un procedimiento para la obtencion de cemento-hormigon

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401